Table 4 Pooled estimates for BCVA change from baseline for PDT versus anti-VEGF
Outcome of Interest | Studies (n) | WMD/OR (95 % CI) | Test for Overall Effect | Study Heterogeneity | ||
|---|---|---|---|---|---|---|
χ2 | p | I2 | ||||
LogMAR Change in both Groups (PDT group vs anti-VEGF group) (3mo) | ||||||
Design | ||||||
All trials | 5 | −0.02 (−0.12, 0.08) | Z =0.45, P =0.653 | 6.77 | 0.148 | 40.9 % |
Retro | 4 | −0.05 (−0.18, 0.07) | Z =0.85, P =0.407 | 5.10 | 0.165 | 41.2 % |
RCT | 1 | 0.05 (−0.07, 0.17) | Z =0.83, P =0.407 | - | ||
Anti-VEGF agents | ||||||
All trials | 5 | −0.02 (−0.12, 0.08) | Z =0.45, P =0.653 | 6.77 | 0.148 | 40.9 % |
Ranibizumab | 3 | −0.03 (−0.20, 0.13) | Z =0.39, P =0.694 | 6.71 | 0.035 | 70.2 % |
Non- Ranibizumab | 2 | −0.02 (−0.16, 0.12) | Z =0.32, P =0.749 | 0.02 | 0.859 | 0.00 % |
LogMAR Change in both Groups (PDT group vs anti-VEGF group) (6mo) | ||||||
Design | ||||||
All trials | 4 | 0.02 (−0.12, 0.16) | Z =0.23, P =0.817 | 7.60 | 0.055 | 60.5 % |
Retro | 3 | −0.03 (−0.22, 0.17) | Z =0.25, P =0.800 | 5.74 | 0.057 | 65.2 % |
RCT | 1 | 0.10 (−0.02, 0.22) | Z =1.66, P =0.097 | - | ||
Anti-VEGF agents | ||||||
All trials | 4 | 0.02 (−0.12, 0.16) | Z =0.23, P =0.817 | 7.60 | 0.055 | 60.5 % |
Ranibizumab | 3 | 0.02 (−0.15, 0.20) | Z =0.27, P =0.787 | 7.21 | 0.027 | 72.3 % |
Non- Ranibizumab | 1 | −0.03 (−0.27, 0.21) | Z =0.25, P =0.806 | - | ||
LogMAR Improvements in both Groups (PDT group vs anti-VEGF group) (12mo) | ||||||
Design | ||||||
All trials | 4 | 0.02 (−0.15, 0.18) | Z =0.20, P =0.839 | 10.43 | 0.015 | 71.2 % |
Retro | 3 | −0.04 (−0.24, 0.16) | Z =0.40, P =0.690 | 5.99 | 0.050 | 66.6 % |
RCT | 1 | 0.15 (0.03, 0.27) | Z =2.49, P =0.013 | - | ||
Anti-VEGF agents | ||||||
All trials | 4 | 0.02 (−0.15, 0.18) | Z =0.20, P =0.839 | 10.43 | 0.015 | 71.2 % |
Ranibizumab | 3 | 0.03 (−0.17, 0.24) | Z =0.31, P =0.760 | 9.63 | 0.009 | 79.0 % |
Non- Ranibizumab | 1 | −0.05 (−0.29, 0.19) | Z =0.41, P =0.682 | - | ||
LogMAR Improvements in both Groups (PDT group vs anti-VEGF group) (24mo) | ||||||
All trials | 2 | −0.17 (−0.90, 0.55) | Z =0.47, P =0.638 | 19.1 | P < 0.001 | 94.8 % |
LogMAR Change as Categorical Variable | ||||||
Proportion of eyes with improved vision | ||||||
final visit | 5 | 1.24 (0.54, 2.85) | Z =0.51, P =0.610 | 7.47 | 0.113 | 46.4 % |
Proportion of eyes with deteriorated vision | ||||||
final visit | 5 | 1.40 (0.42, 4.73) | Z =0.55, P =0.586 | 11.23 | 0.024 | 64.4 % |
Proportion of eyes with stable vision | ||||||
final visit | 5 | 0.56 (0.29, 1.10) | Z =1.67, P =0.094 | 6.82 | 0.145 | 41.4 % |